2024-01-23 16:29:32 ET
Summary
- Genmab's appeal against Johnson & Johnson in an arbitration case has been denied, eliminating the potential upside for the company.
- Despite this setback, Genmab remains well positioned to create shareholder value through continued revenue growth and pipeline progression and expansion.
- The launch of Epkinly/Tepkinly and the growth of other products are expected to reduce Genmab's reliance on Darzalex royalties.
- The head-to-head phase 2 data of GEN3014 and Darzalex represent the most important clinical catalyst for Genmab this year.
I was surprised to see shares of Genmab ( GMAB ) trade lower on the announcement that the arbitration appeal against partner Johnson & Johnson ( JNJ ) was denied . I already had written off this arbitration when it was initially lost and believed the odds of an appeal win were very low....
Read the full article on Seeking Alpha
For further details see:
Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)